미국 - 영어 - NLM (National Library of Medicine)

a-s medication solutions - hydrocortisone (unii: wi4x0x7bpj) (hydrocortisone - unii:wi4x0x7bpj), neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k) - for the treatment of superficial bacterial infections of the external auditory canal caused by organisms susceptible to the action of the antibiotics, and for the treatment of infections of mastoidectomy and fenestration cavities caused by organisms susceptible to the antibiotics. this product is contraindicated in those individuals who have shown hypersensitivity to any of its components, and in herpes simplex, vaccinia, and varicella infections.

미국 - 영어 - NLM (National Library of Medicine)

hi-tech pharmacal co. inc. - neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297) - neomycin sulfate 500 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of neomycin sulfate tablets and other antibacterial drugs, neomycin sulfate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidimiology and susceptibility patterns may contribute to the empiric selection of therapy. suppression of intestinal bacteria : neomycin sulfate tablets are indicated as adjunctive therapy as part of a regimen for the suppression of the normal bacterial flora of the bowel, eg, preoperative preparation of the bowel. it is given concomitantly with erythromycin enteric-coated base (see dosage and administration section) . hepatic coma (portal-systemic encephalopathy) : neomycin sulfate has been shown to be effective adjunctive therapy in hepatic com

미국 - 영어 - NLM (National Library of Medicine)

xgen pharmaceuticals djb, inc. - neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297) - neomycin sulfate 500 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of neomycin sulfate tablets, usp and other antibacterial drugs, neomycin sulfate tablets, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. neomycin sulfate tablets, usp are indicated as adjunctive therapy as part of a regimen for the suppression of the normal bacterial flora of the bowel, e.g. preoperative preparation of the bowel. it is given concomitantly with erythromycin enteric-coated base (see dosage and administration section) . neomycin sulfate has been shown to be effective adjunctive therapy in hepatic coma by reduction of the ammonia-forming bacteria in the intestinal

미국 - 영어 - NLM (National Library of Medicine)

actavis pharma, inc. - neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k) - neomycin 40 mg in 1 ml - neomycin and polymyxin b sulfates solution for irrigation is indicated for short-term use (up to 10 days) as a continuous irrigant or rinse in the urinary bladder of abacteriuric patients to help prevent bacteriuria and gram-negative rod septicemia associated with the use of indwelling catheters. since organisms gain entrance to the bladder by way of, through, and around the catheter, significant bacteriuria is induced by bacterial multiplication in the bladder urine, in the mucoid film often present between catheter and urethra, and in other sites. urinary tract infection may result from the repeated presence in the urine of large numbers of pathogenic bacteria. the use of closed systems with indwelling catheters has been shown to reduce the risk of infection. a three-way closed catheter system with constant neomycin-polymyxin b bladder rinse is indicated to prevent the development of infection while using indwelling catheters. if uropathogens are isolated, they should be identified and tested for susceptibi

미국 - 영어 - NLM (National Library of Medicine)

lannett company, inc. - neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297) - neomycin 500 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of neomycin sulfate tablets and other antibacterial drugs, neomycin sulfate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. suppression of intestinal bacteria neomycin sulfate tablets are indicated as adjunctive therapy as part of a regimen for the suppression of the normal bacterial flora of the bowel, e.g., preoperative preparation of the bowel. it is given concomitantly with erythromycin enteric-coated base (see dosage and administration ). hepatic coma (portal-systemic encephalopathy) neomycin sulfate has been shown to be effective adjunctive therapy in hepatic coma by reduction o

미국 - 영어 - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297) - neomycin 500 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of neomycin sulfate tablets, usp and other antibacterial drugs, neomycin sulfate tablets, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. neomycin sulfate tablets are indicated as adjunctive therapy as part of a regimen for the suppression of the normal bacterial flora of the bowel, eg, preoperative preparation of the bowel. it is given concomitantly with erythromycin enteric-coated base (see dosage and administration ). neomycin sulfate has been shown to be effective adjunctive therapy in hepatic coma by reduction of the ammonia-forming bacteria in the intestinal tract. the subsequent r

미국 - 영어 - NLM (National Library of Medicine)

breckenridge pharmaceutical, inc. - neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297) - neomycin 350 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of neomycin sulfate tablets usp and other antibacterial drugs, neomycin sulfate tablets usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. suppression of intestinal bacteria:   neomycin sulfate tablets are indicated as adjunctive therapy as part of a regimen for the suppression of the normal bacterial flora of the bowel, e.g., preoperative preparation of the bowel. it is given concomitantly with erythromycin enteric-coated base (see dosage and administration section). hepatic coma (portal-systemic encephalopathy):   neomycin sulfate has been shown to be effective adjunctive therapy in hepati

영국 - 영어 - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - hydrocortisone; neomycin sulfate; polymyxin b sulfate - ear drops - 10mg/1ml ; 3400unit/1ml ; 10000unit/1ml

영국 - 영어 - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - hydrocortisone; neomycin sulfate; polymyxin b sulfate - ear drops - 10mg/1ml ; 3400unit/1ml ; 10000unit/1ml

영국 - 영어 - MHRA (Medicines & Healthcare Products Regulatory Agency)

sigma pharmaceuticals plc - hydrocortisone; neomycin sulfate; polymyxin b sulfate - ear drops - 10mg/1ml ; 3400unit/1ml ; 10000unit/1ml